JAK2 Mutation Test

What Does a JAK2 Mutation Test Measure?

The test detects:

• Presence or absence of the JAK2 V617F mutation — the most common genetic alteration in MPNs.
• Mutational status — helps determine whether the mutation is homozygous or heterozygous.
• Bone marrow activity — helps assess whether abnormal cell growth is due to a myeloproliferative neoplasm.

If JAK2 V617F is negative but suspicion of an MPN remains, additional tests for JAK2 Exon 12, CALR, or MPL mutations may be recommended.

JAK2 Mutation Test: Who Needs It and Why It’s Done

What Symptoms May Call for a JAK2 Mutation Test?

Your doctor may recommend a JAK2 Mutation Test if you have:

• Elevated red blood cell, platelet, or white blood cell counts on a routine blood test.
• Symptoms of MPNs, such as fatigue, dizziness, headaches, blurred vision, or unexplained weight loss.
• An enlarged spleen (splenomegaly).
• Unexplained blood clots or thrombosis.
• Unusual bleeding or bruising.

Who Should Get a JAK2 Mutation Test?

This test is recommended for:

• Individuals with suspected myeloproliferative disorders, such as PV, ET, or PMF.
• Patients showing persistent abnormal blood counts without clear cause.
• People with unexplained thrombosis (especially in unusual locations like the hepatic or mesenteric veins).
• Individuals being evaluated for bone marrow disorders.

Why is a JAK2 Mutation Test Done?

The JAK2 Mutation Test helps:

• Confirm a diagnosis of Polycythaemia Vera, Essential Thrombocythaemia, or Primary Myelofibrosis.
• Differentiate MPNs from reactive causes of increased blood cells.
• Assess the risk of blood clots and other complications.
• Guide targeted therapy decisions using JAK inhibitors.
• Monitor treatment response and disease progression.

Importance of a JAK2 Mutation Test

The presence of the JAK2 V617F mutation is a key diagnostic marker for myeloproliferative neoplasms.

Detecting this mutation helps your doctor determine:

• The type and severity of the blood disorder.
• Whether you may benefit from targeted medications that block JAK2 activity.
• The risk of thrombosis and disease transformation.

A negative result does not completely rule out MPNs but indicates the need for further testing for other mutations such as JAK2 Exon 12, CALR, or MPL.

JAK2 Mutation Test Booking & Reports – Metropolis Healthcare

How to Book the JAK2 Mutation Test and Get Your Reports

1. Book Online
   Visit the Metropolis Healthcare website or app and select JAK2 Mutation Test.
2. Choose Collection Option
   Opt for home sample collection or visit your nearest Metropolis Lab.
3. Sample Collection
   3 ml of blood is collected in an EDTA vacutainer.
4. Laboratory Testing
   The test is performed using Real-Time Polymerase Chain Reaction (RT-PCR) at NABL & CAP accredited labs.
5. Accurate Reporting
   Receive your results by 7:00 PM the next day, accessible via email, WhatsApp, or the Metropolis app.

Is Home Sample Collection for JAK2 Mutation Test Available Near You?

Yes. Metropolis Healthcare provides safe and reliable home collection services for the JAK2 Mutation Test. Our trained phlebotomists ensure hygienic sample collection and timely delivery to the lab for processing.

How Long Does It Take to Get a JAK2 Mutation Test Report?

Reports are usually available by the next day once the sample reaches the laboratory.
Note: Turnaround time may vary by location.

Where Can I See or Get JAK2 Mutation Test Results?

Results can be viewed through the Metropolis Healthcare website or mobile app. Reports are also shared via email or WhatsApp, and printed copies can be collected from any Metropolis lab.

Interpreting JAK2 Mutation Test Results

What Your JAK2 Mutation Test Results May Indicate

All results should be correlated with clinical findings and complete blood count (CBC) reports.

How Should You Prepare for a JAK2 Mutation Test?

This test requires no special preparation. However, to ensure accuracy:

• No fasting required — you can eat and drink normally before the test.
• Avoid sample contamination — ensure proper blood collection and labelling.
• Inform your doctor about any ongoing medications or treatments.
• Provide your medical history, including prior test results and clinical symptoms.

How Is a JAK2 Mutation Test Done? (Step-by-Step Procedure)

The JAK2 Mutation Test involves a simple blood collection process followed by genetic analysis:

• Preparation: A tourniquet is tied to your upper arm to make veins visible.
• Collection: About 3 ml of blood is drawn into an EDTA vacutainer.
• Processing: The sample undergoes Real-Time PCR (RT-PCR) to detect the presence or absence of the JAK2 V617F mutation.
• Result: The report indicates whether the mutation is positive or negative.

Conditions That May Affect JAK2 Mutation Test Accuracy

• Low concentration of mutated cells (mutation below detection level).
• Presence of PCR inhibitors in the sample.
• Testing performed too early or with an inadequate specimen.

Diseases That a JAK2 Mutation Test Can Help Detect

• Polycythaemia Vera (PV)
• Essential Thrombocythaemia (ET)
• Primary Myelofibrosis (PMF)
• Myeloproliferative Neoplasms (MPNs)
• Unexplained Thrombosis (e.g., hepatic or mesenteric vein clots)

JAK2 Mutation Test Price in Different Cities

The cost of a JAK2 Mutation Test may vary depending on your location. Here's a table showing the approximate price range for the JAK2 Mutation Test at Metropolis Healthcare in major Indian cities:

The JAK2 Mutation Test cost may vary depending on the city and the specific tests included in the panel. However, Metropolis Healthcare offers competitive JAK2 Mutation Test prices across major cities in India.

References

1. Lee H.J. et al. (2012). Clinical significance of JAK2 V617F mutation in myeloproliferative neoplasms. Clinical Cancer Research, 18(22):7001–7010. PMID: 23209034
2. Ha J.S. et al. (2012). JAK2 mutations in myeloproliferative disorders: Diagnostic and prognostic implications. Ann Lab Med, 32(6):385–391. PMCID: PMC3486931
3. Indian Council of Medical Research. (2010). JAK2 mutation analysis in polycythaemia and thrombocythaemia patients. Indian J Med Res, 132:423–427.
4. Baxter E.J. et al. (2005). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365(9464):1054–1061. PMID: 15781101
5. Kralovics R. et al. (2005). A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 352(17):1779–1790. PMID: 15858187